News

The patent was issued by the United States Patent and Trademark Office (USPTO) and will be listed in the US Food and Drug Administration’s Approved Drug Products with

Repatha is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol

The fifth patient is the third and final patient to be dosed in Cohort 2. The three patients in Cohort 2 received a dose of TT-034 of 1.25

"We are pleased by the FDA’s acceptance of our BLA for Zinbryta, which we believe has the potential to help people living with MS," said Gilmore O’Neill, vice

Xilonix is designed to block chronic inflammation associated with malignant tumor growth. The US Phase III trial was initially launched in March 2013 and patients were enrolled at

Opdivo is a programed death-1 (PD-1) immune checkpoint inhibitor that has received approval from the FDA as a monotherapy in two cancer indications. The sBLA is based on

Kybella is a cytolytic drug, which when injected into the fat under the chin destroys the cell membrane. When injected into submental fat, the drug works by destroying

Brilinta is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs) and it works by inhibiting platelet activation. The sNDA is

Earlier this month, Mylan offered to buy Perrigo in a deal valued at nearly $29bn, under which Perrigo shareholders would receive $205 per share. However, board of directors